ANEB Stock Financials: Financial Performance and Reports

Period	FY-2023	FY-2022	FY-2021	FY-2020
Period Ended	06/30/2023	06/30/2022	06/30/2021	06/30/2020
Operating Revenue	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$0.00	$0.00	$0.00	$0.00
Gross Profit	$0.00	$0.00	$0.00	$0.00
Gross Profit Ratio	0	0	0	0
Research and Development Expenses	$5.60 M	$2.96 M	$2.27 M	$150,000.00
General & Administrative Expenses	$6.18 M	$3.87 M	$1.34 M	$140,106.00
Selling & Marketing Expenses	$0.00	$0.00	$0.00	$23,210.00
Selling, General & Administrative Expenses	$6.18 M	$3.87 M	$1.34 M	$23,351.00
Other Expenses	-$41,146.00	-$1,777.00	-$1,344.00	$0.00
Operating Expenses	$11.78 M	$6.83 M	$3.61 M	$173,351.00
Cost And Expenses	$11.78 M	$6.83 M	$3.61 M	$173,351.00
Interest Income	$92,407.00	$7,332.00	$1,020.00	$7.72
Interest Expense	$0.00	$7,332.00	$11,767.00	$1,286.00
Depreciation & Amortization	$11,783.00	$5,555.00	-$324.00	$1.04 M
EBITDA	-$11.78 M	-$6.83 M	-$3.61 M	-$173,350.00
EBITDA Ratio	0	0	0	0
Operating Income	-$11.78 M	-$6.83 M	-$3.61 M	-$173,350.00
Operating Income Ratio	0	0	0	0
Total Other Income/Expenses Net	-$41,146.00	$5,555.00	-$26.64 M	-$1,287.00
Income Before Tax	-$11.73 M	-$6.83 M	-$30.25 M	-$174,637.00
Income Before Tax Ratio	0	0	0	0
Income Tax Expense	-$104,190.60	-$12,887.00	$10,747.00	-$1,040.11
Net Income	-$11.73 M	-$6.81 M	-$30.26 M	-$174,637.00
Net Income Ratio	0	0	0	0
EPS	-0.47	-0.29	-1.3	-0.0074
EPS Diluted	-0.47	-0.29	-1.3	-0.0074
Weighted Average Shares Out	$25.07 M	$23.34 M	$23.34 M	$23.72 M
Weighted Average Shares Out Diluted	$25.07 M	$23.34 M	$23.34 M	$23.72 M
Link

Anebulo Pharmaceuticals, Inc. (ANEB) Financials